FDA approves new indication for Amgen’s leukemia drug Blincyto

This article was originally published here

The US Food and Drug Administration (FDA) has approved Amgen’s supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) for B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission in adults and children.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply